Special Issue "Advances in Cancer Immunotherapy and Vaccines Research"
Deadline for manuscript submissions: 1 February 2023 | Viewed by 24
Interests: tumor vaccine; T-cells; peptides; adjuvants; head and neck cancer
Special Issues, Collections and Topics in MDPI journals
Immunotherapy has emerged as a standard therapy in addition to surgical resection, chemotherapy, and radiotherapy. The oncological outcome of immune checkpoint blockades is acceptable in a variety of tumor types, indicating immune cells’ ability to kill tumors. The drawback of immune checkpoint blockades is their low responder rate of around 20%. As the effect of immune checkpoint blockades depends on already-existing immune cells in the tumor microenvironment, the lack, or exhaustion, of these cells hinders the antitumor effect of this treatment. A tumor vaccine specifically increases antitumor immune cells. In addition to CD8 T-cells, which play an essential role in tumor vaccination by directly killing tumor cells, innumerable reports have indicated that CD4 T-cells also have direct cytotoxic activity against tumors. The identification of peptide epitopes from tumor-associated antigens (TAA) could aid the development of a tumor vaccine. However, vaccination using tumor-derived peptides and inadequate adjuvants, such as incomplete Freund’s adjuvant (IFA), which consists of non-metabolizable oil and a surfactant, failed to achieve clinical antitumor effects in the late 20th century. With advances in the understanding of the immune system, we now have a solid theory for the expansion of T-cells by combining peptides (T-cell receptor stimulation as signal 1, costimulatory molecules as signal 2, and cytokines as signal 3) using adequate adjuvants and impeding the immune-suppressive environment. This Special Issue will gather the latest advances in the field of tumor immunology to optimize a tumor vaccine.
Potential topics for this Special Issue include, but are not limited to, the following:
- Immune adjuvants for a tumor vaccine;
- Immunological assessment of the tumor microenvironment;
- Combination of immunotherapy and chemoradiotherapy;
- Optimization of administration route and/or formula in a tumor vaccine;
- Immune cell polarization and immunotherapy;
- Impeding immune suppression in the tumor microenvironment;
- Re-education of immune cells in the tumor microenvironment;
Dr. Takumi Kumai
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor vaccine
- immune adjuvants
- tumor immune environment
- peptide vaccine
- suppressive immune cells
- checkpoint inhibitors